Cytomegalovirus Infection Renal Transplant Recipients: Risk Factors and Outcome

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2156-2158

  Kanter, J ^a   Pallardo L ^a   Gavela, E ^a   Escudero, V ^a   Beltran S ^a   Morales, A ^a   Avila A ^a   Crespo, J F ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; ANTIGENS, VIRAL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68949218373     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.057     Document Type: Article

References (12)

1. Becker B.N., Becker Y.T., Leverson G.E., et al. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 39 (2002) 1088
2. Pérez-Sola M.J., Castón J.J., Solana R., et al. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Cli{dotless}́n 26 (2008) 38
3. Nett P., Hesey D., Fernandez L., et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 78 (2004) 1036
4. Lopez-Rocafort L., and Brennan D.C. Current review of cytomegalovirus in renal transplantation. Min Urol Nefrol 53 (2001) 145
5. Sarmiento J.M., Dockrell D.H., Schwab T.R., et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 14 (2000) 136
6. Cytomegalovirus. Am J Transplant 4 suppl 10 (2004) 51
7. Trotter J.F., Wallack A., and Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-days corticosteroid taper. Transpl Infect Dis 5 (2003) 174
8. Kalil A.C., Levitsky J., Lyden E., et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 (2005) 870
9. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611
10. Humar A., Mazzulli T., Mouzza G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 5 (2005) 1065
11. Boeckh M. Impact of neutropenia on post transplant management of cytomegalovirus. Clinician 22 (2005) 22
12. Fishman J.A., Emery V., Freeman R., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21 (2007) 149